Does Flecainide Disturb Sleep?
Yes, flecainide can cause sleep disturbances, specifically insomnia, though this occurs infrequently (1-3% of patients), and the drug may also cause morbid dreams in less than 1% of patients.
Evidence from FDA Drug Labeling
The FDA-approved prescribing information for flecainide explicitly lists insomnia as a psychiatric adverse effect occurring in 1% to less than 3% of patients 1. Additionally, "morbid dreams" are documented as occurring in less than 1% of patients 1. These sleep-related adverse effects are formally recognized in the drug's safety profile.
Clinical Context and Frequency
While sleep disturbances are documented with flecainide, they are relatively uncommon compared to the drug's more frequent adverse effects:
- Most common non-cardiac effects include dizziness (18.9%), visual disturbances (15.9%), dyspnea (10.3%), headache (9.6%), nausea (8.9%), and fatigue (7.7%) 1
- Sleep-related issues (insomnia and morbid dreams) fall into the less common category
- In clinical trials, only 5.4% of patients discontinued flecainide due to non-cardiac adverse effects overall 1
Practical Considerations
When prescribing flecainide, counsel patients that:
- Insomnia may occur but is uncommon (1-3% incidence)
- Vivid or disturbing dreams are possible but rare (<1%)
- These effects tend to be intermittent and may decrease over time 2
- Most adverse effects become evident early in therapy 2
If sleep disturbances develop:
- Consider dose timing (taking earlier in the day if on twice-daily dosing)
- Evaluate whether symptoms are tolerable, as many side effects diminish with continued use
- Rule out other causes of sleep disruption, including the underlying arrhythmia itself or concurrent medications
- Reassess the risk-benefit ratio, particularly in patients without structural heart disease where flecainide is safest 3, 4
Important Safety Context
While sleep disturbances are a minor concern, the primary safety considerations with flecainide remain cardiac: proarrhythmia, conduction abnormalities, and negative inotropic effects 5. The drug is contraindicated in patients with structural heart disease, particularly those with prior myocardial infarction or left ventricular dysfunction 3, 4, 5.